FrançaisAre analysts right about Sarepta Therapeutics (SRPT)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Sarepta Therapeutics, we replayed every analyst price target of the past 12 months and measured the real outcome: 31% were profitable, average return -4% (336 calls). At 3 months: -3% average return (37% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Needham | 42 | 21% | -22% |
| RBC Capital | 29 | 24% | -16% |
| B of A Securities | 27 | 22% | -0% |
| Morgan Stanley | 19 | 47% | +13% |
| Piper Sandler | 17 | 12% | -20% |
Frequently asked questions
Is Sarepta Therapeutics a buy right now?
The analyst consensus on Sarepta Therapeutics (SRPT) is "Hold" (11 bullish, 7 bearish calls over 12 months). This is not advice: historically, 31% of their targets on this stock turned out profitable over 1 year.
What is Sarepta Therapeutics's price target?
The median 12-month price target is $27.00 (+25% vs $21.59), ranging from $13.00 to $37.00 (5 analysts).
Are analysts accurate on Sarepta Therapeutics?
Over 1 year, 31% of analyst targets on Sarepta Therapeutics were profitable, for an average return of -4% (across 336 timestamped calls). This is JPI Invest's accuracy metric.
What is the Sarepta Therapeutics stock forecast?
Analysts target a median of $27.00 within 12 months, i.e. +25% vs the current price. The most bullish targets $37.00, the most cautious $13.00.
What is the Sarepta Therapeutics stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $27.00, +25%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (31%), and the stock's past trajectory.
Is Sarepta Therapeutics overvalued?
Detailed valuation data for Sarepta Therapeutics is available in the interactive analysis.
📊 See the full interactive analysis of Sarepta Therapeutics →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.